Clinical data | |
---|---|
Trade names | Ethmozine |
Other names | Moricizine (USAN US) |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a601214 |
Pregnancy category |
|
ATC code | |
Pharmacokinetic data | |
Bioavailability | 34–38% |
Protein binding | 95% |
Elimination half-life | 3–4 hours (healthy volunteers), 6–13 hours (cardiac disease) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.046.216 |
Chemical and physical data | |
Formula | C22H25N3O4S |
Molar mass | 427.52 g·mol−1 |
3D model (JSmol) | |
| |
|
Moracizine[1] or moricizine, sold under the trade name Ethmozine, is an antiarrhythmic of class IC.[2] It was used for the prophylaxis and treatment of serious and life-threatening ventricular arrhythmias,[3] but was withdrawn in 2007 for commercial reasons.[4]